7
Participants
Start Date
September 2, 2020
Primary Completion Date
July 29, 2022
Study Completion Date
July 29, 2022
Lixivaptan
Oral vasopressin V2 receptor antagonist
Northeast Clinical Research Center, LLC, Bethlehem
Nephrology Associates of Northern Virginia, Inc., Fairfax
Brookview Hills Research Associates, LLC, Winston-Salem
Mayo Clinic, Rochester
University of Chicago Medicine & Biological Sciences, Chicago
University of California Los Angeles, Los Angeles
Lead Sponsor
Collaborators (1)
Centessa Pharmaceuticals plc
INDUSTRY
Palladio Biosciences
INDUSTRY